A list of the latest medical information from Seagull Pharmacy

Current Location：Home>Medical Information

Addition of Bevacizumab to Ixabepilone Is Effective, Tolerable in Platinum-Resistant Ovarian Cancer
2022-02-24 11:15:41
The combination of ixabepilone (Ixempra) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) vs ixabepilone alone in...
Apatinib Yields High Clinical Benefit in Thyroid Cancer
2022-02-24 11:10:25
A prolonged survival benefit and tolerable safety profile were observed in patients with advanced or metastatic radioactive iodine-refractory dif...
Several Cancer Biosimilars Appear Clinically Indistinguishable Vs Reference Products
2022-02-24 11:06:49
Patients who were treated with cancer biosimilars and underwent extensive clinical evaluations experienced indistinguishable efficacy compared wi...
Frontline Checkpoint Inhibition Shows Potential in mRCC With Poor Performance Status
2022-02-23 11:12:18
The combinations of nivolumab ( Opdivo ) plus ipilimumab ( Yervoy ) and pembrolizumab ( Keytruda ) plus axitinib ( Inlyta ) demonstrated ...
First-Line Nivolumab Combos Yield Improved OS Vs Chemo Alone in Esophageal Cancer
2022-02-23 11:09:02
Treatment with nivolumab ( Opdivo ) plus chemotherapy or nivolumab plus ipilimumab ( Yervoy ) in the first-line setting resulted in longer ov...
Atezolizumab/Bevacizumab Demonstrates Comparable OS to Sunitinib for Metastatic RCC
2022-02-23 11:03:07
Atezolizumab ( Tecentriq ) plus bevacizumab (Avastin) demonstrated comparable overall survival (OS) to sunitinib (Sutent) for patients with met...
TERAVOLT Study Identifies 7 Factors Associated with COVID-19 Mortality in Thoracic Cancer
2022-02-23 10:58:31
Seven significant determinates of mortality have been identified for patients with thoracic malignancies who have contracted COVID-19, according ...
FDA Grants Fast Track Designation to IO-202 for R/R AML
2022-02-22 11:22:36
IO-202, a LILRB4 checkpoint inhibitor, has been granted a fast track designation by the FDA for the treatment of patients with relapsed or refrac...
FDA Approves FoundationOne CDx to Identify MSI-High Cancers for Pembrolizumab Therapy
2022-02-22 11:19:37
The FDA has announced approval of FoundationOne CDx as a companion diagnostic for identifying people with microsatellite instability (MSI)–high c...
Recommended Dose of Ceritinib Yields Promising Early Activity in in ALK+ Malignancies
2022-02-22 11:11:55
Treatment with the 500 mg/m2 recommended dose of ceritinib ( Tepmetko ) once daily with food resulted in promising antitumor activity in relaps...

<<
<
7
8
9
>
>>
Jump to Page